Reuters logo
2 months ago
BRIEF-Lysogene completes enrollment in first international pivotal observational study in MPS IIIA
May 30, 2017 / 5:06 AM / 2 months ago

BRIEF-Lysogene completes enrollment in first international pivotal observational study in MPS IIIA

1 Min Read

May 30 (Reuters) - LYSOGENE SA:

* LYSOGENE COMPLETES ENROLLMENT IN FIRST INTERNATIONAL PIVOTAL OBSERVATIONAL STUDY IN MPS IIIA

* CONSENSUALLY AGREED ASSESSMENT TOOLS (BSID-III, VABS-II) FOR COGNITIVE ASSESSMENT & BEHAVIOR

* ‍Recruitment of 23 Patients in Less Than a Year​

* HAS ALSO SUCCESSFULLY COMPLETED A PHASE I/II TRIAL AND 5-YEAR FOLLOW-UP STUDY OF FOUR MPS IIIA PATIENTS WITH NO ADVERSE EVENTS RELATED TO TREATMENT

* INTERNATIONAL MULTI-CENTER STUDY IS TO FUNCTION AS NON-CONCURRENT CONTROL GROUP FOR UPCOMING LYSOGENE PHASE II/III PIVOTAL GENE THERAPY TRIAL, SCHEDULED TO START DURING Q1 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below